Fibronectin- and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins α5β1 and αvβ5

被引:99
作者
Milner, Richard
Crocker, Stephen J.
Hung, Stephanie
Wang, Xiaoyun
Frausto, Ricardo F.
del Zoppo, Gregory J.
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA
关键词
D O I
10.4049/jimmunol.178.12.8158
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early in the pathogenesis of multiple sclerosis, the blood-brain barrier is compromised, which leads to deposition of the plasma proteins fibronectin and vitronectin in cerebral parenchyma. In light of our previous finding that microglial activation in vitro is strongly promoted by fibronectin and vitronectin, we set out to examine the possibility that modulation of microglial activation by fibronectin or vitronectin is an important regulatory mechanism in vivo. In an experimental autoimmune encephalomyelitis mouse model of demyelination, total brain levels of fibronectin and vitronectin were strongly increased and there was a close relationship between fibronectin and vitronectin deposition, microglial activation, and microglial expression of matrix metalloproteinase-9. In murine cell culture, flow cytometry for MHC class I and gelatin zymography revealed that microglial activation and expression of pro-matrix metalloproteinase-9 were significantly increased by fibronectin and vitronectin. Function-blocking studies showed that the influence of fibronectin and vitronectin was mediated by the alpha(5)beta(1) and alpha(v)beta(5) integrins, respectively. Taken together, this work suggests that fibronectin and vitronectin deposition during demyelinating disease is an important influence on microglial activation state. Furthermore, it provides the first evidence that the alpha(5)beta(1) and alpha(v)beta(5) integrins are important mediators of microglial activation.
引用
收藏
页码:8158 / 8167
页数:10
相关论文
共 97 条
[1]  
ADAMS JC, 1993, DEVELOPMENT, V117, P1183
[2]   Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke [J].
Anthony, DC ;
Ferguson, B ;
Matyzak, MK ;
Miller, KM ;
Esiri, MM ;
Perry, VH .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1997, 23 (05) :406-415
[3]   Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS [J].
Anthony, DC ;
Miller, KM ;
Fearn, S ;
Townsend, MJ ;
Opdenakker, G ;
Wells, GMA ;
Clements, JM ;
Chandler, S ;
Gearing, AJH ;
Perry, VH .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 87 (1-2) :62-72
[4]   Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes [J].
Arai, K ;
Lee, SR ;
Lo, EH .
GLIA, 2003, 43 (03) :254-264
[5]   Matrix metalloproteases and tumor invasion [J].
Arribas, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :2020-2021
[6]   The blood-brain barrier: an overview - Structure, regulation, and clinical implications [J].
Ballabh, P ;
Braun, A ;
Nedergaard, M .
NEUROBIOLOGY OF DISEASE, 2004, 16 (01) :1-13
[7]   Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion [J].
Barnett, MH ;
Prineas, JW .
ANNALS OF NEUROLOGY, 2004, 55 (04) :458-468
[8]   Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists [J].
Bi, X ;
Gall, CM ;
Zhou, J ;
Lynch, G .
NEUROSCIENCE, 2002, 112 (04) :827-840
[9]   Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions [J].
Bo, L ;
Peterson, JW ;
Mork, S ;
Hoffman, PA ;
Gallatin, WM ;
Ransohoff, RM ;
Trapp, BD .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (10) :1060-1072
[10]   DETECTION OF MHC CLASS-II ANTIGENS ON MACROPHAGES AND MICROGLIA, BUT NOT ON ASTROCYTES AND ENDOTHELIA IN ACTIVE MULTIPLE-SCLEROSIS LESIONS [J].
BO, L ;
MORK, S ;
KONG, PA ;
NYLAND, H ;
PARDO, CA ;
TRAPP, BD .
JOURNAL OF NEUROIMMUNOLOGY, 1994, 51 (02) :135-146